1. Li Y, Wang J. Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment. BMC Nephrol 2024; 25: 140.
2.
Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy. Life Sci 2020; 259: 118379.
3.
Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med 2016; 164: 406-16.
4.
Dalen JE, Alpert JS, Goldberg RJ, et al. The epidemic of the 20(th) century: coronary heart disease. Am J Med 2014; 127: 807-12.
5.
Nakahara T, Dweck MR, Narula N, et al. Coronary artery calcification: from mechanism to molecular imaging. JACC Cardiovasc Imaging 2017; 10: 582-93.
6.
Berman DS, Arnson Y, Rozanski A, et al. Coronary artery calcium scanning: the agatston score and beyond. JACC Cardiovasc Imaging 2016; 9: 1417-9.
7.
Tramontano L, Punzo B, Clemente A, et al. Prognostic value of coronary calcium score in asymptomatic individuals: a systematic review. J Clin Med 2022; 11: 5842.
8.
Detrenis S, Meschi M, Bertolini L, Savazzi G. Contrast medium administration in the elderly patient: is advancing age an independent risk factor for contrast nephropathy after angiographic procedures? J Vasc Interv Radiol 2007; 18: 177-85.
9.
Mehran R, Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; 100: S11-5.
10.
Wang J, Zhang C, Liu Z, Bai Y. Risk factors of contrast-induced nephropathy after percutaneous coronary intervention: a retrospective analysis. J Int Med Res 2021; 49: 3000605211005972.
11.
Kimura Y, Tsukui D, Kono H. Uric acid in inflammation and the pathogenesis of atherosclerosis. Int J Mol Sci 2021; 22: 12394.
12.
Kimura Y, Yanagida T, Onda A, et al. Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation. Arterioscler Thromb Vasc Biol 2020; 40: 570-82.
13.
Mendi MA, Afsar B, Oksuz F, et al. Uric acid is a useful tool to predict contrast-induced nephropathy. Angiology 2017; 68: 627-32.
14.
Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-9.
15.
Abellás-Sequeiros RA, Raposeiras-Roubín S, Abu-Assi E, et al. Mehran contrast nephropathy risk score: Is it still useful 10 years later? J Cardiol 2016; 67: 262-7.
16.
Bundhun PK, Sookharee Y, Bholee A, et al. Application of the SYNTAX score in interventional cardiology: a systematic review and meta-analysis. Medicine (Baltimore) 2017; 96: e7410.
17.
Farooq V, Head SJ, Kappetein AP, et al. Widening clinical applications of the SYNTAX Score. Heart 2014; 100: 276-87.
18.
Oduncu V, Erkol A, Karabay CY, et al. Relation of the severity of contrast induced nephropathy to SYNTAX score and long term prognosis in patients treated with primary percutaneous coronary intervention. Int J Cardiol 2013; 168: 3480-5.
19.
Nasir K, Cainzos-Achirica M. Role of coronary artery calcium score in the primary prevention of cardiovascular disease. BMJ 2021; 373: n776.
20.
Osugi N, Suzuki S, Shibata Y, et al. Coronary artery calcification scores improve contrast-induced nephropathy risk assessment in chronic kidney disease patients. Clin Exp Nephrol 2017; 21: 391-7.
21.
Jenny NS, Brown ER, Detrano R, et al. Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2010; 209: 226-9.
22.
Torngren K, Rylance R, Björk J, et al. Association of coronary calcium score with endothelial dysfunction and arterial stiffness. Atherosclerosis 2020; 313: 70-5.
23.
Wu L, Tiwari MM, Messer KJ, et al. Peritubular capillary dysfunction and renal tubular epithelial cell stress following lipopolysaccharide administration in mice. Am J Physiol Renal Physiol 2007; 292: F261-8.
24.
Guo X, Li Y, Yang Y, et al. Noninvasive markers of arterial stiffness and renal outcomes in patients with chronic kidney disease. J Clin Hypertens (Greenwich) 2021; 23: 823-30.
25.
Yun HR, Joo YS, Kim HW, et al. Coronary artery calcification score and the progression of chronic kidney disease. J Am Soc Nephrol 2022; 33: 1590-601.
26.
Li X, Bayliss G, Zhuang S. Cholesterol crystal embolism and chronic kidney disease. Int J Mol Sci 2017; 18: 1120.
27.
Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis 2000; 36: 1089-109.
28.
Takahashi K, Omuro A, Ohya M, et al. Incidence, risk factors, and prognosis of cholesterol crystal embolism because of percutaneous coronary intervention. Am J Cardiol 2022; 167: 15-9.
29.
Modolo R, Figueiredo VN, Moura FA, et al. Coronary artery calcification score is an independent predictor of the no-reflow phenomenon after reperfusion therapy in acute myocardial infarction. Coron Artery Dis 2015; 26: 562-6.
